Article
Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
Molecular therapy : the journal of the American Society of Gene Therapy - 1 Jul 2001
Atencio I A, Avanzini J B, Johnson D, Neuteboom S, Vaillancourt M T, Nielsen L L, Hajian G, Sutjipto S, Sugarman B J, Philopena J, McAllister D L, Beltran J C, Nodelman M, Ramachandra M, Wills K N
Abstract excerpt
TP53 is the most commonly altered tumor-suppressor gene in cancer and is currently being tested in Phase II/III gene replacement trials. Many tumors contain wild-type TP53 sequence with elevated MDM2 protein levels, targeting p53 for degradation. These tumors are more refractory to treatment with exogenous wild-type p53. Here we generate a recombinant adenovirus expressing a p53 variant, rAd-p53 (d 13-19), that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.